PROGNOSTIC SIGNIFICANCE OF SERUM ALBUMIN IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRERITUXIMAB AND RITUXIMAB ERA
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most frequent subgroup of non-Hodgkin lymphoma. The aim of the author was to verify the existence of important pretreatment serum albumin (SA) level as an independent factor of disease prognosis in patients with DLBCL in the territory of Southeast Serbia, in the era of prerituximab and rituximab.
A total of 55 patients with DLBCL (R-CHOP group) and 14 patients (CHOP group) were included in the study. Patients were divided into 2 groups according to the value of pretreatment SA: SA 30 g/l and ≤ 30 g/l. We analyzed the correlation of SA value with clinical stage and age, as well as the survival of patients with DLBCL compared to SA according to a therapeutic protocol.
There was no significant correlation of SA with age (p = 0.630), clinical stage (p = 0.943) and survival (p = 0.638) in CHOP group. There was significant correlation between SA levels with survival (p = 0.001) in R-CHOP group. No significant correlation of SA with age (p = 0.141) and clinical stage of disease (p = 0.305). There was no significant difference in survival compared to the value of SA in CHOP group/Log-rank = 0.782. There was significant difference in survival compared to the value of SA in R-CHOP group/Log-rank = 0.002.
The relationship between the predictive value of SA and the treatment protocol for DLBCL evaluated by the logistic regression analysis showed that the level of SA was not a significant predictor for the choice of treatment (Wald = 1.540, p > 0.05)
Our research has confirmed a negative predictive value of pretreatment serum albumin levels in patients with DLBCL treated according to R-CHOP protocol. Retrospective studies with a larger number of DLBCL patients who were treated with CHOP protocol, would give more significant results for the predictive importance of SA. Prognostic indexes, which as part of the point system include the value of SA, can be very useful in predicting patients with DLBCL.
References
Alici S, Bavbek S.E, Kaytan E, Eralp Y, Onat H. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2003;26(1):1-5. [CrossRef] [PubMed]
Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 2016;34(4):184-92. [CrossRef] [PubMed]
Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H et al. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol 2010; 84(6):493-8. [CrossRef] [PubMed]
Cowan R.A, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer 1989;59(2):276-82. [CrossRef] [PubMed]
Dalia S, Chavez J, Bello C, Chervenick P, Little B, Al Ali N et al. A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prog-nostic Index (A-IPI). Blood 2013;122(21):4267. [CrossRef]
Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee J et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014;93:1305-12. [CrossRef] [PubMed]
Dixon MR, Haukoos JS, Udani SM, Naghi JJ, Arnell TD, Kumar RR et al. Carcinoembryonic antigen and albu-min predict survival in patients with advanced colon and rectal cancer. Arch Surg 2003;138(9):962-6. [CrossRef] [PubMed]
Eatrides J, Thompson Z, Lee J, Bello C, Dalia S. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lym-phoma. Ann Hematol 2014;94(2):357-8. [CrossRef] [PubMed]
Feng R. The international staging system predicts outcome in diffuse large B-cell lymphoma treated with R-CHOP. Experimental hematology 2015;43(9):S62. [CrossRef]
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010;9:69. [CrossRef] [PubMed]
Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR et al. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J 2014;55(6):1568-75. [CrossRef] [PubMed]
Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara T, Isa R et al. The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer Journal 2016;6,e383; [CrossRef] [PubMed]
Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Annals of Hematology 2015;94(1):57-63. [CrossRef] [PubMed]
Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 2004;8(8):1041-8. [CrossRef] [PubMed]
McMillan D.C, Watson W.S, O'Gorman P, Preston T, Scott H.R, McArdle C.S. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39(2):210-13. [CrossRef] [PubMed]
Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP et al. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituxi-mab. Leuk Lymphoma 2008;49(3):462-9. [CrossRef] [PubMed]
Nikolaides C, Dimou S, Pavlidis N. Prognostic Factors in Aggressive Non-Hodgkin’s Lymphomas. The Onco-logist 1998;3:189-97. [CrossRef] [PubMed]
Praksah G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK. B cell non-Hodgkin's lymphoma: Experi-ence from a tertiary care cancer center. Ann Hematol 2012;91(10):1603-11. [CrossRef] [PubMed]
Seymour J, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13(3):575-82. [CrossRef] [PubMed]
Stasi R, Conforti M, Del Poeta G, Simone MD, Coppetelli U, Tribalto M et al. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica 1992;77(6):518-21. [PubMed]
Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 2009;9:288. [CrossRef] [PubMed]
Trikha M, Corringham R, Klein B, Rossi J-F. Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evi-dence. Clin Cancer Res 2003;9:4653-65. [PubMed]
Utech A, Tadros E, Hayes T, Garcia J. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012;3(4):245-51. [CrossRef] [PubMed]